Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NVG 291

Next Previous
Drug Profile

NVG 291

Alternative Names: NVG-291; NVG-291-R

Latest Information Update: 11 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NervGen Pharma
  • Class Antidementias; Neuroprotectants; Peptides; Vascular disorder therapies
  • Mechanism of Action Receptor-like protein tyrosine phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal cord injuries
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Spinal cord injuries
  • Phase I Alzheimer's disease; Multiple sclerosis
  • Preclinical Stroke
  • Research Amyotrophic lateral sclerosis

Most Recent Events

  • 02 Jun 2025 NervGen Pharma plans to meet US FDA to discuss development plan for NVG 291
  • 02 Jun 2025 Efficacy and adverse events data from phase I/II CONNECT trials in Spinal cord injuries released by NervGen Pharma
  • 03 Apr 2025 Pharmacodynamics data from a preclinical trial in Spinal cord injuries released by NervGen Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top